GPR17: A New Hybrid Receptor for Nucleotides and Cysteinyl-LTs
Author Information
Author(s): Chiara Parravicini, Graziella Ranghino, Maria P. Abbracchio, Piercarlo Fantucci
Primary Institution: University of Milan
Hypothesis
Can GPR17 serve as a therapeutic target for stroke by understanding its structure and ligand binding features?
Conclusion
GPR17's nucleotide binding occurs in similar regions as known P2Y receptors, but with distinct binding characteristics.
Supporting Evidence
- GPR17 is a hybrid GPCR that responds to both purinergic and cysteinyl-LT ligands.
- Molecular dynamics simulations revealed similarities in the binding pocket of GPR17 and P2Y receptors.
- GPR17's structure suggests it may have a dual binding mechanism for different types of ligands.
Takeaway
GPR17 is a special receptor that can respond to two different types of signals, which could help in treating strokes.
Methodology
The study involved molecular modeling and dynamics simulations to explore the 3-D structure of GPR17 and its ligand binding.
Limitations
The pharmacological agents used are not selective for GPR17, which may complicate the interpretation of results.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website